Replimune (REPL) is facing "significant risk" related to its ongoing phase 3 trial of RP1 in melanoma after the US Food and Drug Administration rejected the company's biologics license application for the product candidate, Wedbush Securities said in a note.
Wedbush downgraded its rating on Replimune to neutral from outperform, with a lower price target of $2 from $19.
Shares sank 64% following an increase in intraday trading volume to over 53.9 million from a daily average of about 1.84 million.
Children's Place (PLCE) reported a fiscal Q4 adjusted loss and a decline in revenue from a year ago late Friday.
Shares slumped 26% as intraday trading volume soared to more than 1.39 million from a daily average of about 276,000.
Fastenal (FAST) reported Q1 earnings and sales Monday in line with the FactSet consensus.
Its shares were down 7%, with intraday trading volume at more than 10.9 million, compared with the stock's daily average of about 8.68 million.
Price: $1.69, Change: $-3.08, Percent Change: -64.60%